ReviewJournal of cellular and molecular medicine2026
Targeting Ferroptosis With Natural Products for the Treatment of Skeletal System Disease: An Updated Review.
Review in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Skeletal system diseases, encompassing chronic disorders of the skeletal system which commonly include osteoarthritis, rheumatoid arthritis, osteoporosis and osteosarcoma. Their incidence rates have been increasing in recent years, resulting in significant social and economic burdens. However, their pathogenesis remains inadequately explored. Ferroptosis, a recently identified form of regulated cell death, differs from other cell death mechanisms, such as apoptosis and autophagy, by primarily involving iron metabolism and lipid peroxidation. The underlying mechanism of ferroptosis is characterised by intracellular iron overload and accumulation of ROS, both of which contribute to the onset of osteoarthritis, rheumatoid arthritis and osteoporosis and are closely linked to the malignancy of osteosarcoma. To enhance understanding of ferroptosis' potential role in the pathophysiology and treatment of skeletal system diseases, this review examines its relationship with these conditions, the mechanisms involved and the therapeutic potential of natural compounds in modulating ferroptosis. By investigating the contribution of ferroptosis to the occurrence and progression of these diseases, novel clinical targets for diagnosis and treatment are proposed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.